Population differences in platinum toxicity as a means to identify novel genetic susceptibility variants

Pharmacogenetics and Genomics

Volumn 20, Issue 5, 2010, Pages 327-337

  Eileen Dolan, M ^a,b   O'Donnell, Peter H ^a,b   Gamazon, Eric ^c   Zhang, Wei ^a   Stark, Amy L ^c   Kistner Griffin, Emily O ^d   Stephanie Huang, R ^a,b  

^a Section of Hematology/Oncology   (United States)

^b Committee on Clinical Pharmacology and Pharmacogenomics ^*  (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Interethnic differences; Pharmacogenomic susceptibility; Platinum chemotherapy

Indexed keywords

CARBOPLATIN; CISPLATIN; HISTONE H3; PLATINUM;

ARTICLE; ASIAN; CAUCASIAN; CONTROLLED STUDY; DNA ADDUCT; GENE EXPRESSION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; HUMAN CELL; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; RACE DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM;

AFRICAN CONTINENTAL ANCESTRY GROUP; ASIAN CONTINENTAL ANCESTRY GROUP; CARBOPLATIN; CELL LINE, TRANSFORMED; CISPLATIN; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENETICS, POPULATION; GENOME-WIDE ASSOCIATION STUDY; HUMANS; INHIBITORY CONCENTRATION 50; LYMPHOCYTES; PHARMACOGENETICS; PHENOTYPE; PLATINUM;

EID: 77951438750     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3283396c4e     Document Type: Article

References (42)

1. Rabik CA, Dolan ME Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007; 33:9-23.
2. Celik I, Kars A, Ozyar E, Tekuzman G, Atahan L, Firat D. Major toxicity of cisplatin, fluorouracil, and leucovorin following chemoradiotherapy in patients with nasopharyngeal carcinoma [comment]. J Clin Oncol 1996; 14:1043-1044. (Pubitemid 26085555)
3. Van Glabbeke M, Renard J, Pinedo HM, Cavalli F, Vermorken J, Sessa C, et al. Iproplatin and carboplatin induced toxicities: overview of phase II clinical trial conducted by the EORTC Early Clinical Trials Cooperative Group (ECTG). Eur J Cancer Clin Oncol 1988; 24:255-262. (Pubitemid 18051195)
4. Dolan ME, Newbold KG, Nagasubramanian R, Wu X, Ratain MJ, Cook EH Jr, Badner JA. Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicity. Cancer Res 2004; 64:4353-4356. (Pubitemid 38802443)
5. Shukla SJ, Duan S, Wu X, Badner JA, Kasza K, Dolan ME. Whole-genome approach implicates CD44 in cellular resistance to carboplatin. Human Genomics 2009; 3:128-142.
6. Millward MJ, Boyer MJ, Lehnert M, Clarke S, Rischin D, Goh BC, et al. Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patients. Ann Oncol 2003; 14:449-454. (Pubitemid 36367424)
7. Watanabe A, Taniguchi M, Sasaki S. Induction chemotherapy with docetaxel, cisplatin, fluorouracil and l-leucovorin for locally advanced head and neck cancers: a modified regimen for Japanese patients. Anti-Cancer Drugs 2003; 14:801-807. (Pubitemid 38339784)
8. Ogawara M, Kawahara M, Hosoe S, Atagi S, Kawaguchi T, Okishio K, et al. A feasibility study of paclitaxel 225 mg/m(2) and carboplatin AUC = 6 in untreated advanced non-small cell lung cancer patients in Japan. Jpn J Clin Oncol 2002; 32:48-53. (Pubitemid 41288784)
9. Takei Y, Suzuki M, Ohwada M, Saga Y, Kohno T, Machida S, Sato I. A feasibility study of paclitaxel and carboplatin therapy in Japanese patients with epithelial ovarian cancer. Oncol Reports 2003; 10:951-955.
10. Huang RS, Duan S, Bleibel WK, Kistner EO, Zhang W, Clark TA, et al. A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity. Proc Natl Acad Sci USA 2007; 104:9758-9763. (Pubitemid 47175340)
11. Huang RS, Duan S, Shukla SJ, Kistner EO, Clark TA, Chen TX, et al. Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach. Am J Hum Genet 2007; 81:427-437. (Pubitemid 47330203)
12. Duan S, Bleibel WK, Huang RS, Shukla SJ, Wu X, Badner JA, Dolan ME. Mapping genes that contribute to daunorubicin-induced cytotoxicity. Cancer Res 2007; 67:5425-5433. (Pubitemid 46997283)
13. International HapMap C: a haplotype map of the human genome [see comment]. Nature 2005; 437:1299-1320.
14. Gossage L, Madhusudan S. Current status of excision repair cross complementing-group 1 (ERCC1) in cancer. Cancer Treatment Rev 2007; 33:565-577. (Pubitemid 47355341)
15. Suk R, Gurubhagavatula S, Park S, Zhou W, Su L, Lynch TJ, et al. Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients. Clin Cancer Res 2005; 11:1534-1538. (Pubitemid 40315237)
16. Kotti S, Bickeboller H, Clerget-Darpoux F. Strategy for detecting susceptibility genes with weak or no marginal effect [erratum appears in Hum Hered 2008; 65:119]. Hum Heredity 2007; 63:85-92.
17. Shukla SJ, Dolan ME. Use of CEPH and non-CEPH lymphoblast cell lines in pharmacogenetic studies. Pharmacogenomics 2005; 6:303-310.
18. Huang RS, Kistner EO, Bleibel WK, Shukla SJ, Dolan ME. Effect of population and gender on chemotherapeutic agent-induced cytotoxicity. Mol Cancer Ther 2007; 6:31-36.
19. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81:559-575. (Pubitemid 47330214)
20. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc 1995; B(57):289-300.
21. Stranger BE, Nica AC, Forrest MS, Dimas A, Bird CP, Beazley C, et al. Population genomics of human gene expression. Nat Genet 2007; 39:1217-1224. (Pubitemid 47482691)
22. Dixon AL, Liang L, Moffatt MF, Chen W, Heath S, Wong KC, et al. A genome-wide association study of global gene expression. Nat Genet 2007; 39:1202-1207. (Pubitemid 47482680)
23. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci USA 2003; 100:9440-9445. (Pubitemid 37033947)
24. Nicolae DL, Gamazon E, Zhang W, Duan S, Dolan ME, Cox NJ. Trait associated SNPs are more likely to be eQTLs: annotation to enhance discovery from GWAS. PLoS Genet 2010; (in press).
25. Galea AM, Murray V. The interaction of cisplatin and analogues with DNA in reconstituted chromatin. Biochim Biophys Acta 2002; 1579:142-152. (Pubitemid 35341436)
26. Ransom M, Dennehey BK, Tyler JK. Chaperoning histones during DNA replication and repair. Cell 140:183-195.
27. Wu B, Droge P, Davey CA. Site selectivity of platinum anticancer therapeutics. Nat Chem Biol 2008; 4:110-112.
28. Wang D, Lippard SJ. Cisplatin-induced post-translational modification of histones H3 and H4. J Biol Chem 2004; 279:20622-20625. (Pubitemid 38656456)
29. Nakatani K, Nishioka J, Itakura T, Nakanishi Y, Horinouchi J, Abe Y, et al. Cell cycle-dependent transcriptional regulation of calmodulin-binding transcription activator 1 in neuroblastoma cells. Intl J Oncol 2004; 24:1407-1412.
30. Henrich KO, Fischer M, Mertens D, Benner A, Wiedemeyer R, Brors B, et al. Reduced expression of CAMTA1 correlates with adverse outcome in neuroblastoma patients. Clin Cancer Res 2006; 12:131-138. (Pubitemid 43166186)
31. Gottfried E, Faust S, Fritsche J, Kunz-Schughart LA, Andreesen R, Miyake K, Kreutz M. Identification of genes expressed in tumor-associated macrophages. Immunobiology 2003; 207:351-359. (Pubitemid 37258645)
32. Shukla SJ, Duan S, Badner JA, Wu X, Dolan ME. Susceptibility loci involved in cisplatin-induced cytotoxicity and apoptosis. Pharmacogenet Genomics 2008; 18:253-262. (Pubitemid 351323240)
33. Wang L, Lu J, An J, Shi Q, Spitz MR, Wei Q. Polymorphisms of cytosolic serine hydroxymethyltransferase and risk of lung cancer: a case-control analysis. Lung Cancer 2007; 57:143-151. (Pubitemid 47043184)
34. Filipski KK, Loos WJ, Marsh S, Verweij J, Sparreboom A. Effect of genetic variation in ABCC2 on the renal clearance of cisplatin. Clin Pharmacol Ther 2009; 85 (Suppl 1):S66.
35. Torgerson DG, Boyko AR, Hernandez RD, Indap A, Hu X, White TJ, et al. Evolutionary processes acting on candidate cis-regulatory regions in humans inferred from patterns of polymorphism and divergence. PLoS Genet 2009; 5:e1000592.
36. Huang SM, Temple R. Is this the drug or dose for you? Impact and consideration of ethnic factors in global drug development, regulatory review, and clinical practice. Clin Pharmacol Ther 2008; 84:287-294.
37. Yasuda SU, Zhang L, Huang SM. The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies. Clin Pharmacol Ther 2008; 84:417-423.
38. Maitland ML, Ratain MJ, Cox NJ. Interpreting P values in pharmacogenetic studies: a call for process and perspective [comment]. J Clin Oncol 2007; 25:4513-4515.
39. Su B, Xiao J, Underhill P, Deka R, Zhang W, Akey J, et al. Y-Chromosome evidence for a northward migration of modern humans into Eastern Asia during the last ice age. Am J Hum Genet 1999; 65:1718-1724. (Pubitemid 30468685)
40. Spielman RS, Bastone LA, Burdick JT, Morley M, Ewens WJ, Cheung VG. Common genetic variants account for differences in gene expression among ethnic groups [see comment]. Nat Genet 2007; 39:226-231. (Pubitemid 46184354)
41. He M, Gitschier J, Zerjal T, de Knijff P, Tyler-Smith C, Xue Y. Geographical affinities of the HapMap samples. PLoS ONE [Electronic Resource] 2009; 4:e4684.
42. Hirschhorn JN, Daly MJ. Genome-wide association studies for common diseases and complex traits. Nat Rev Genet 2005; 6:95-108. (Pubitemid 40179532)